Sign in

Peter Thompson

@thompsonisletlab.bsky.social
82 followers 46 following 10 posts

Associate Prof at UManitoba, Islet biology and Type 1 Diabetes focus.

PostsRepliesMedia
Peter Thompson @thompsonisletlab.bsky.social · 24/07/2026
New paper from the lab! 🎉 reliable antibodies are the cornerstone of our work! New studies by Jasmine in our group identified a reliable antibody for detecting notoriously difficult cell cycle protein p16INK4a in mouse and human! www.tandfonline.com/doi/full/10.... @dreamdiabetes.bsky.social
tandfonline.com
Importance of antibody validation in detecting cell cycle regulatory protein p16 INK4A by immunohistochemistry on pancreas tissue
p16INK4A is a cyclin-dependent kinase inhibitor that plays important roles in pancreatic islet beta-cell maturation, function, and senescence. As staining pattern consistency and reproducibility ha...
072
Peter Thompson @thompsonisletlab.bsky.social · 24/07/2026
New paper from our lab 🎉How do IFN response and senescence relate in T1D? New work led by Roozbeh Motlagh in our group shows they are largely distinct responses in human islets and SC islet cells! www.tandfonline.com/doi/full/10....
tandfonline.com
IFNα and bleomycin-induced DNA damage activate distinct stress responses in human islets and induced pluripotent stem cell-derived islet cells
Pancreatic β-cells undergo different stress responses during the development of type 1 diabetes (T1D), such as the type I interferon (IFN) response and senescence. Although the IFN response leads t...
031
Peter Thompson @thompsonisletlab.bsky.social · 06/04/2026
How are we learning from #T1D trials and moving towards precision medicine? Congrats 🎉to Jasmine in the lab on writing a fantastic review article on this topic at Diabetes, Obesity and Metabolism! dom-pubs.onlinelibrary.wiley.com/doi/10.1111/...
dom-pubs.onlinelibrary.wiley.com
Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy
Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset i...
032
Peter Thompson @thompsonisletlab.bsky.social · 20/11/2025
📢🎉New study from our lab on circulating SASP factors suggests a novel senescent cell biomarker across #T1D stages! Congrats🥳Camille Jasmine and @dream-diabetes.bsky.social trainees Grateful to TrialNet @chrimanitoba.bsky.social @cirtn.bsky.social www.nature.com/articles/s41...
nature.com
Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort - Scientific Reports
Scientific Reports - Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort
0105
Peter Thompson @thompsonisletlab.bsky.social · 14/11/2025
🎉Very excited to share our new work on senescence and insulin processing now out in @DiabetologiaJnl link.springer.com/article/10.100… Fantastic effort by my @dream-diabetes.bsky.social trainees, along with @yichunchen.bsky.social @bruceverchere.bsky.social @cirtn.bsky.social
link.springer.com
2188
Peter Thompson @thompsonisletlab.bsky.social · 11/06/2025
Very excited to share new work on the origins of beta cell senescence in #T1D led by talented PhD student Jasmine Pipella! 🥂🎉 online today! diabetesjournals.org/diabetes/art...
diabetesjournals.org
Autoreactive T Cells and Cytokine Stress Drive β-Cell Senescence Entry and Accumulation in Type 1 Diabetes
Type 1 diabetes (T1D) results from a complex dialogue between the immune system and islets characterized by T cell–mediated autoimmune destruction of pancr
4217
Peter Thompson @thompsonisletlab.bsky.social · 09/04/2025
📢The lab turned 5 in March 😲... where did the time go? Looking forward to celebrating our 5th anniversary all year long with more great science and the fantastic trainees and staff that encourage me everyday! 🥂😄
040